By proceeding, you agree to our Terms of Use and Privacy Policy.
FibroFind is a rapidly developing biomedical sciences company that has a deep understanding of fibrosis biology and has employed this knowledge to design bespoke biological assays with human tissues that can determine if a novel drug is able to preve
09-11 November 2022
Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies.
Event Ended
USA
Paid
Boston
29-01 December 2022
Welcome to the 6th Obesity & NASH Drug Development Summit There has been a rise and fall of investment in NASH in the wake of highly demanding biopsy endpoints and late-stage clinical setbacks.
07-09 March 2023
The surge of clinical approvals in CKD and unprecedented use of surrogate endpoints in rare kidney diseases have catalysed a new era of complimentary therapies and precision medicine in drug development for kidney disease.
12-13 July 2023
The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encourage
13-14 September 2023
LSX World Congress USA 2023 is a premier event that brings together the most influential and visionary leaders in the life science industry. This two-day executive conference, taking place in Boston in September 2023, offers a unique platform for CEO
19-21 September 2023
Welcome to the 7th IPF Summit, where we gather to explore the forefront of scientific advancements in the field of idiopathic pulmonary fibrosis (IPF). This comprehensive, three-day conference brings together experts and innovators from around the wo